JAZZ — Jazz Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $13.92bn
- $16.07bn
- $4.27bn
RCS - Redx Pharma Limited - US FDA lifts Partial Clinical Hold on Zelasudil
Brief: Jazz Pharmaceuticals Announce Positive Efficacy From Ziihera Phase 3 Trial
Explainer: What will change with the US reclassification of marijuana?
Explainer: What will change if the US reclassifies marijuana?
U.S. RESEARCH ROUNDUP- Autodesk, Crowdstrike, Zscaler
U.S. STOCKS ON THE MOVE-TransAlta, Johnson & Johnson, E.W. Scripps
U.S. STOCKS ON THE MOVE-Sunoco, Albemarle, GE Healthcare Technologies
U.S. STOCKS ON THE MOVE-OSI Systems, AEP, TransAlta
U.S. STOCKS ON THE MOVE- Alphabet, Quantum Computing, Jazz Pharma
Jazz Pharma jumps after cancer drug meets main goal in late-stage study
Brief: Positive Herizon-GEA-01 Phase 3 Results Support Ziihera As Her2-Targeted Agent-Of-Choice And Ziihera Combination Regimens As New Standard Of Care In First-Line Her2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma
Brief: Jazz Pharmaceuticals Showcases New Clinical And Translational Data For Modeyso
Jazz Pharmaceuticals Q3 revenue beats estimates
Brief: Jazz Pharmaceuticals Q3 Adjusted EPS USD 8.13 Vs. IBES Estimate USD 5.97
U.S. RESEARCH ROUNDUP-Avery Dennison, Expedia Group, Hologic
Brief: Jazz Pharmaceuticals To Report Third Quarter Financial Results On November 5, 2025
US FDA approves Jazz Pharma's combination therapy for lung cancer (updated)
Brief: FDA Approves Lurbinectedin With Atezolizumab/Atezolizumab,Hyaluronidase-Tqjs For Type Of Lung Cancer
US FDA approves Jazz Pharma's therapy for lung cancer